Crystalys Therapeutics focuses on developing new therapeutics to address significant unmet medical needs for people living with gout. The company is actively advancing its pipeline through clinical development, including ongoing Phase 3 studies. Their work aims to provide improved treatment options for patients managing this condition.
Funding
$205M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPNHFounders
Product
Problem
Patients with gout often experience recurrent flares, chronic joint damage, and comorbidities due to insufficiently effective or poorly tolerated urate‑lowering therapies. Existing options may require complex dosing, have drug‑drug interaction risks, or fail to achieve target serum uric acid levels in a substantial subset of patients. This therapeutic gap leads to reduced quality of life and higher long‑term healthcare utilization.
Solution
Crystalys Therapeutics is advancing a novel oral urate‑lowering agent, Dotinurad, designed to selectively inhibit the renal urate transporter URAT1, thereby enhancing urinary excretion of uric acid. The compound exhibits a favorable pharmacokinetic profile that supports once‑daily dosing and minimizes off‑target activity. In Phase III trials, Dotinurad has demonstrated statistically significant reductions in serum uric acid compared with placebo, with a safety record comparable to existing standards of care. The company integrates a data‑driven clinical development platform to accelerate enrollment, monitor biomarkers, and streamline regulatory submissions. Upon approval, the therapy will be positioned as a next‑generation option for patients inadequately controlled on current agents, aiming to reduce flare frequency and improve joint health.
Target Audience
The primary customers are rheumatologists and primary‑care physicians who prescribe urate‑lowering therapy, as well as health‑system formularies and payors seeking cost‑effective, evidence‑based treatments for gout management.
Features
- Highly selective URAT1 inhibition mechanism that maximizes uric acid clearance while limiting renal adverse effects
- Oral tablet formulation optimized for rapid dissolution and consistent bioavailability across fed and fasted states
- Phase III clinical data showing ≥30 % greater serum uric acid reduction versus placebo with a comparable adverse‑event profile
- Integrated pharmacodynamic modeling to personalize dosing and predict long‑term outcomes in diverse patient populations
- Scalable GMP manufacturing process leveraging continuous flow synthesis to ensure batch‑to‑batch consistency
- Regulatory strategy aligned with FDA’s Fast Track and Breakthrough Therapy pathways to expedite market entry
- Post‑marketing surveillance framework employing real‑world evidence analytics for ongoing safety monitoring